Spectrum of AIDS defining opportunistic infections in a series of 77 hospitalised HIV-infected Omani patients

Sultan Qaboos University Medical Journal

Volumn 12, Issue 4, 2012, Pages 442-448

  Balkhair, Abdullah A ^a   Al Muharrmi, Zakariya K ^b   Ganguly, Shyam ^b   Al Jabri, Ali A ^b  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

AIDS; HIV; Oman; Opportunistic infections

Indexed keywords

EID: 84870704462     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.12816/0003169     Document Type: Article

References (32)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS World AIDS Day Report. From: www.unaids.org/en/media/unaids/contentassets/ documents/unaidspublication/2011/JC2216_ WorldAIDSday_report_2011_en.pdf. Accessed: May 2012.
2. Centers for Disease Control. Revised Surveillance Case Definitions for HIV Infection among Adults, Adolescents, and Children aged <18 Months and for HIV Infection and AIDS among Children aged 18 Months to <13 Years-United States, 2008. MMWR 2008; 57:RR-10.
3. Seage GR 3rd, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002; 30:421-8.
4. Ministry of Health, Oman. Community Health and Disease Surveillance Newsletter. Vol. 17, Iss. 1, Muscat: Ministry of Health. From: www.unaids. org/./2010progressreportssubmittedbycountries/ oman_2010_country_progress_report_en.pdf. Accessed: Jul 2010.
5. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9.
6. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
7. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999; 13:1687-95.
8. Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, et al. Human immunodeficiency virus type 1 infection in Oman: Antiretroviral therapy and frequencies of drug resistance mutations. AIDS Res Hum Retroviruses 2004; 20:1166-72.
9. Kaiser Family Foundation. Reported Number of People Receiving Antiretroviral Therapy. From:http:// www.globalhealthfacts.org/topic.jsp?i=10&dsp=c. Accessed: Jul 2010.
10. Perbost I, Malafronte B, Pradier C, Santo LD, Dunais B, Counillon E, et al. In the era of highly active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection? HIV Med 2005; 6:232-9.
11. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005; 37:482-7.
12. Mojumdar K, Vajpayee M, Chauhan NK, Mendiratta S. Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health 2010; 10:416.
13. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: A consensus definition. HIV Med 2011; 12:61-4.
14. Naba MR, Kanafani ZA, Awar GN, Kanj SS. Profile of opportunistic infections in HIV-infected patients at a tertiary care center in Lebanon. J Infect Public Health 2010; 3:130-3.
15. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301-6.
16. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-5.
17. Sharma S, Dhungana GP, Pokhrel BM, Rijal BP. Opportunistic infections in relation to CD4 level among HIV seropositive patients from central Nepal. Nepal Med Coll J 2010; 12:1-4.
18. Kaur A, Babu PG, Jacob M, Narasimhan C, Ganesh A, Saraswathi NK, et al. Clinical and laboratory profile of AIDS in India. J Acquir Defic Synd 1992; 5:883-9.
19. Ayyagari A, Sharma AK, Prasad KN, Dhole TN, Kishore J, Chaudhary G. Spectrum of opportunistic infections in HIV infected cases in a tertiary care hospital. Indian J Med Microbiol 1999; 17:78-80.
20. Chan CK, Alvarez Bognar F, Wong KH, Leung CC, Tam CM, Chan KC, et al. The epidemiology and clinical manifestations of human immunodeficiency virus-associated tuberculosis in Hong Kong. Hong Kong Med J 2010; 16:192-8.
21. Kumaraswamy N, Solomon S. Spectrum of opportunistic infections among AIDS patient in Tamil Nadu, India. Int J STD AIDS 1995; 6:447-9.
22. Santos Mde L, Ponce MA, Vendramini SH, Villa TC, Santos NS, Wysocki AD, et al. The epidemiological dimension of TB/HIV co-infection. Rev Lat Am Enfermagem 2009; 17:683-8.
23. Harrington M. From HIV to tuberculosis and back again: A tale of activism in 2 pandemics. Clin Infect Dis 2010; 50:S260-6.
24. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: The epidemiology and the response. Clin Infect Dis 2010; 50:S201-7.
25. Swaminathan S, Nagendran G. HIV and tuberculosis in India. J Biosci 2008; 33:527-37.
26. Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: A metaanalysis. Clin Infect Dis 2001; 33:1922-30.
27. Assefa S, Erko B, Medhin G, Assefa Z, Shimelis T. Intestinal parasitic infections in relation to HIV/ AIDS status, diarrhea and CD4 T-cell count. BMC Infect Dis 2009 9:155.
28. O'Hara SP, Small AJ, Gajdos GB, Badley AD, Chen XM, Larusso NF. HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum. J Infect Dis 2009; 199:1195-204.
29. Tzipori S, Widmer G. A hundred-year retrospective on cryptosporidiosis. Trends Parasitol 2008; 24:184-9.
30. Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al. Profile of neurological disorders associated with HIV/AIDS from Bangalore, South India (1986-96). Indian J Med Res 2000; 111:14-23.
31. Machala L, Malý M, Hrdá S, Rozsypal H, Stanková M, Kodym P. Antibody response of HIV-infected patients to latent, cerebral and recently acquired toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009; 28:179-82.
32. Nissapatorn V. Toxoplasmosis in HIV/AIDS: A living legacy. Southeast Asian J Trop Med Public Health 2009; 40:1158-78.